New drug rebecsinib enters human testing for tough blood cancers

NCT ID NCT07250646

Recruiting now Disease control Sponsor: Aspera Biomedicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-phase study is testing a new drug called rebecsinib in 28 people whose secondary acute myeloid leukemia or high-risk myelofibrosis has come back or not responded to treatment. The drug is given by IV infusion four times per 28-day cycle for up to six cycles. The main goals are to find the safest dose and check for side effects, while also looking for any signs that the drug is shrinking the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rebecsinib (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat secondary AML or myelofibrosis.
What could go wrong: This is a very early Phase 1 trial with only 28 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug may cause side effects or not work at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS SECONDARY AML

Contacts and locations

Locations

City of Hope Center
RECRUITING

Duarte, California, 91010, United States
UC Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States
UC San Diego Moores Cancer Center
RECRUITING

San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.